Failing External Ventricular Drain Clamp Trials in Aneurysmal Subarachnoid Hemorrhage
A 52-year-old woman with aneurysmal subarachnoid hemorrhage (Hunt-Hess 3, modified Fisher 4) from a ruptured 7 mm anterior communicating artery aneurysm, coiled on day 0. An EVD was placed for acute hydrocephalus. On day 6 she is alert, follows commands, and moves all four limbs. The EVD has been clamped twice for 24 hours. On both trials, ICP rose from a baseline of 12-15 mmHg to 30-34 mmHg within four hours, with headache and drowsiness that resolved within 20 minutes of unclamping. CSF: 5,000 RBCs, protein 90 mg/dL, glucose 60 mg/dL, no organisms. CT shows stable ventricular size and no new infarct. TCD: right MCA 148 cm/s, right ICA 52 cm/s, left MCA 92 cm/s. Serum Na 132 mmol/L.
1. What is the significance of two failed clamp trials, and what is your next step? Include how you would validate that the trials were done correctly.
Read the worked answer
Two symptomatic failures in an awake, examinable patient mean she is shunt-dependent; the next step is a ventriculoperitoneal shunt, not a third trial ad infinitum.
Why:
- The pattern is diagnostic. Each trial produced a reproducible ICP rise to the 30s with headache and drowsiness, and each resolved promptly on unclamping. That is the clinical signature of impaired CSF absorption rather than monitor malfunction or positioning.
- But validate the trial first. A fair trial requires the drain clamped at a defined height (not simply closed), ICP measured continuously and transducer-levelled, no concurrent vasospasm or fever driving the symptoms, and a symptom that is attributable to ICP rather than to the headache of blood breakdown products. Her CT is stable, which supports hydrocephalus over other causes.
- Weigh the alternative of waiting. Prolonged EVDs carry infection risk that rises after day 5-7 (on the order of 5-10% per week in many series), plus hemorrhage and tract complications. She has already failed twice; a third trial buys little and adds risk.
- Shunt timing. Proceed to VP shunt; the main counseling point is that a shunt may need revision and that over-drainage can cause subdural collections.
Document that vasospasm was considered and excluded as the cause of her deterioration before committing to hardware.
2. How do you interpret the TCD findings, and do they change management today?
Read the worked answer
Right MCA velocity of 148 cm/s with an ICA velocity of 52 cm/s gives a Lindegaard ratio of ~2.8 - mild vasospasm, not enough to act on by itself.
Interpretation:
- Velocity alone is nonspecific. High MCA velocity can reflect hyperemia (high flow with a normal ICA) or vasospasm (high MCA with a rising ICA ratio). The Lindegaard ratio separates them: <3 is indeterminate/mild, 3-6 suggests moderate vasospasm, >6 severe.
- She has no deficit. She is alert, follows commands, and moves all four limbs. Asymptomatic mild-to-moderate TCD elevations during the day 5-7 window are common and are monitored, not treated.
- What actually changes management: trending TCDs daily, and a CTA or catheter angiogram if velocities climb above ~200 cm/s, the ratio exceeds 6, or any new focal deficit or decline in consciousness appears. DCI is a clinical and radiographic diagnosis, not a number.
- What should not change: do not start prophylactic induced hypertension or hypervolemia in an asymptomatic patient - triple-H therapy has been abandoned for prophylaxis and adds pulmonary and cerebral edema risk. Maintain euvolemia and normal sodium.
The clamp-trial failure is a hydrocephalus problem; do not let the TCD number distract from that.
3. Her sodium is 132 mmol/L. Does this matter, and how do you manage it in the context of the day-6 SAH patient?
Read the worked answer
Yes - it matters, and it should be corrected with salt, not with free water restriction.
- Why it matters. Hyponatremia in SAH is independently associated with delayed cerebral ischemia, worse outcome, and longer ICU stay. It also lowers the threshold for symptomatic cerebral edema and worsens the clinical picture during clamp trials and vasospasm surveillance.
- The mechanism is usually not SIADH. In SAH, cerebral salt wasting with volume depletion is common, and the two are clinically hard to distinguish at the bedside. This distinction does matter, because fluid restriction - the reflex treatment for SIADH - is harmful if she is volume-depleted.
- Treatment therefore starts with assessment, not restriction. Check volume status (daily weights, fluid balance, CVP/IVC if needed), serum and urine osmolality, and urine sodium. Then give isotonic saline, enteral salt tablets, and, if refractory, hypertonic saline or fludrocortisone. Target 135-140 mmol/L.
- Avoid rapid overcorrection. Correct slowly enough to avoid osmotic demyelination - she is not in the chronic-severe range, but the principle holds.
- Monitor for the mirror problem. Overly aggressive hypertonic therapy in this population produces hypernatremia and volume overload; the goal is euvolemia with a normal sodium.
Her sodium of 132 mmol/L is a small number with a large clinical meaning on day 6 after SAH.